Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Tecvayli“
Suchtreffer
Begriffe & Kennungen
Tecvayli
Eintrag öffnenTecvayli · 4.1 Therapeutic indications · 1
Eintrag öffnenTecvayli · 4.3 Contraindications · 1
Eintrag öffnenTecvayli · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenTecvayli · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenTecvayli · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenTecvayli · 4.5 · No interaction studies have been performed with TECVAYLI.
Eintrag öffnenTecvayli · 4.5 · The initial release of cytokines associated with the start of TECVAYLI treatment could suppress CYP450 enzymes
Eintrag öffnenTecvayli · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenTecvayli · 4.8 Undesirable effects · 1
Eintrag öffnenTecvayli · 4.8 · 16 Table 7: Adverse reactions in multiple myeloma patients treated with TECVAYLI in clinical trials and postma
Eintrag öffnenTecvayli · 4.8 · 17 Gastrointestinal disorders Diarrhoea14 Very common 45 4.2 Nausea Very common 22 0.4 Constipation Very commo
Eintrag öffnenTecvayli · 4.8 · 18 Note: Adverse events are graded according to the NCI-CTCAE Version 5.0, with the exception of ICANS and CRS
Eintrag öffnenTecvayli · 4.8 · 19 Description of selected adverse reactions
Eintrag öffnenTecvayli · 4.8 · Adverse reactions are listed in Table 7 by system organ class and by frequency. Frequency categories are defin
Eintrag öffnenTecvayli · 4.8 · Cytokine release syndrome
Eintrag öffnenTecvayli · 4.8 · Frequency N=739 (all Any Grade 3 or 4 System Organ Class Adverse Reaction grades) Grade (%) (%) Infections and
Eintrag öffnenTecvayli · 4.8 · In clinical trials (monotherapy and combination therapy; N=739) , CRS was reported in 65% of patients followin
Eintrag öffnenTecvayli · 4.8 · In clinical trials (monotherapy and combination therapy; N=739), ICANS was reported in 2.7% of patients receiv
Eintrag öffnenTecvayli · 4.8 · In clinical trials (monotherapy and combination therapy; N=739), in patients who received TECVAYLI at the reco
Eintrag öffnen